Trials / Terminated
TerminatedNCT06140420
Naltrexone for Prolonged Grief Disorder
Naltrexone Treatment for Prolonged Grief Disorder: A Proof of Concept Study
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Texas Tech University · Academic / Other
- Sex
- All
- Age
- 18 Years – 120 Years
- Healthy volunteers
- Accepted
Summary
This is a study to see how effective oral naltrexone is as treatment for prolonged grief disorder (PGD). Participants will take their assigned medication for 8 weeks, with monthly visits to assess symptom severity, social connectedness, and adverse reactions.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Naltrexone Oral Product | Generic, oral tablet. |
| DRUG | Placebo | Oral Placebo |
Timeline
- Start date
- 2023-08-01
- Primary completion
- 2025-02-01
- Completion
- 2025-02-01
- First posted
- 2023-11-20
- Last updated
- 2025-06-08
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06140420. Inclusion in this directory is not an endorsement.